AzizNazhaMD

PubMed

• 7 citations
  Advances in Acute Myeloid Leukemia Genomics, Where Do We Stand in 2018?
  Yazan F. Madanat, Matt Kalaycio, Aziz Nazha
  Acta Medica Academica. 2019-06-26
• 164 citations
  TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups
  Detlef Haase, Kristen E. Stevenson, Donna Neuberg, Jaroslaw P. Maciejewski, Aziz Nazha
  Leukemia. 2019-01-11
• 28 citations
  Distinct clinical and biological implications of CUX1 in myeloid neoplasms.
  Mai Aly, Zubaidah M. Ramdzan, Yasunobu Nagata, Suresh Kumar Balasubramanian, Naoko Hosono
  Blood Advances. 2019-07-23

Journal Articles

• Mutational Landscape of myelodysplastic/myeloproliferative Neoplasm – Unclassifiable (MDS/MPN-U)  
  Aziz Nazha, Rami S Komrokji, Andrew Sochacki, Mikkael A Sekeres, Prithviraj Bose, Courtney D DiNardo, Hagop M Kantarjian, Srdan Verstovsek, Sanam Loghavi, Jaroslaw P M..., Blood
• An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies  
  Padron E, Garcia-Manero G, Patnaik MM, Itzykson R, Lasho T, Nazha A, Rampal RK, Sanchez ME, Jabbour E, Al Ali NH, Thompson Z, Colla S, Fenaux P, Kantarjian HM, Killick..., Blood Cancer J, 1/31/2015
• Fibrogenesis in Primary Myelofibrosis: Diagnostic, Clinical and Therapeutic Implications  
  Nazha A, Khoury JD, Rampal R, Daver N, Oncologist, 1/24/2015
• Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?  
  Nazha A, Sekeres MA, Gore SD, Zeidan AM, Oncologist, 1/20/2015
• Genomic Patterns Associated with Hypoplastic Compared to Hyperplastic Myelodysplastic Syndromes  
  Nazha A, Seastone D, Radivoyevitch T, Przychodzen B, Carraway HE, Patel BJ, Carew J, Makishima H, Sekeres MA, Maciejewski JP, Haematologica, 1/13/2015
• The Revised International Prognostic Scoring System (IPSS-R) is not Predictive of Survival in Patients with Secondary Myelodysplastic Syndromes  
  Nazha A, Seastone DJ, Keng M, Hobson S, Kalaycio M, Maciejewski JP, Sekeres MA, Leukemia Lymphoma, 1/1/2015
• Paroxysmal nocturnal hemoglobinuria is not a cause of anemia in patients with myelofibrosis  
  Nazha A, Jorgensen JL, Verstovsek S, Leuk Lymphoma, 1/24/2014
• Characteristics of Sweet Syndrome in Patients With Acute Myeloid Leukemia  
  Kazmi SM, Pemmaraju N, Patel KP, Cohen PR, Daver N, Tran KM, Ravandi F, Duvic M, Garcia-Manero G, Pierce S, Nazha A, Borthakur G, Kantarjian H, Cortes J, Clin Lymphoma Myeloma Leuk, 1/24/2014
• Prognostic Implications of Chromosome 17 Abnormalities in the Context of Monosomal Karyotype in Patients With Acute Myeloid Leukemia and Complex Cytogenetics  
  Nazha A, Kantarjian HM, Bhatt VR, et al, Clin Lymphoma Myeloma Leuk, 1/21/2014
• Characteristics and Outcomes of Patients With Multiple Myeloma Who Develop Therapy-Related Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid ...  
  Pemmaraju N, Shah D, Kantarjian H, Orlowski RZ, Nogueras Gonzalez GM, Baladandayuthapani V, Jain N, Wagner V, Garcia-Manero G, Shah J, Ravandi F, Pierce S, Takahashi K..., Clin Lymphoma Myeloma Leuk, 1/15/2014
• Pharmacotherapy of polycythemia vera  
  Tam CS, Nazha A, Verstovsek S, Expert Opinion on Orphan Drugs Dec, 12/1/2013
•  
  Nazha A, Kantarjian H, Ravandi F, Huang X, Choi S, Garcia-Manero G, Jabbour E, Borthakur G, Kadia T, Konopleva M, Cortes J, Ferrajoli A, Kornblau S, Daver N, Pemmaraju..., Am J Hematol, 11/1/2013
• Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months  
  Nazha A, Kantarjian H, Jain P, Romo C, Jabbour E, Quintas-Cardama A, Luthra R, Abruzzo L, Borthakur G, Ravandi F, Pierce S, O'Brien S, Cortes J, Haematologica, 11/1/2013
• Prognostic implications and clinical characteristics associated with bone marrow fibrosis in patients with myelofibrosis  
  Nazha A, Estrov Z, Cortes J, Bueso-Ramos CE, Kantarjian H, Verstovsek S, Leuk Lymphoma, 11/1/2013
• Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse  
  Jain P, Kantarjian H, Patel K, Faderl S, Garcia-Manero G, Benjamini O, Borthakur G, Pemmaraju N, Kadia T, Daver N, Nazha A, Luthra R, Pierce S, Cortes J, Ravandi F, Leuk Lymphoma, 10/9/2013
• Omacetaxine mepesuccinate (synribo) - newly launched in chronic myeloid leukemia  
  Nazha A, Kantarjian H, Cortes J, Quintás-Cardama A, Expert Opin Pharmacother, 10/1/2013
• The clinical impact of ponatinib on the risk of bleeding in patients with chronic myeloid leukemia  
  Nazha A, Romo CG, Kantarjian H, Cortes J, Haematologica, 10/1/2013
• The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia  
  Nazha A, Bueso-Ramos C, Estey E, Faderl S, O'Brien S, Fernandez MH, Nguyen M, Koller C, Freireich E, Beran M, Pierce S, Keating M, Cortes J, Kantarjian H, Ravandi F, Front Oncol, 9/1/2013
• Acute myeloid leukemia in the elderly: do we know who should be treated and how?  
  Nazha A, Ravandi F, Leuk Lymphoma, 8/28/2013
• Biological and Clinical Features of Trisomy 21 in Adult Patients With Acute Myeloid Leukemia  
  Strati P, Daver N, Ravandi F, Pemmaraju N, Pierce S, Garcia-Manero G, Nazha A, Kadia T, Jabbour E, Borthakur G, Faderl S, Quintas-Cardama A, Kantarjian H, Cortes J, Clin Lymphoma Myeloma Leuk, 8/19/2013
• Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy  
  Daver N, Liu Dumlao T, Ravandi F, Pierce S, Borthakur G, Pemmaraju N, Nazha A, Faderl S, Jabbour E, Garcia-Manero G, Cortes J, Kantarjian H, Quintás-Cardama A, Clin Lymphoma Myeloma Leuk, 8/1/2013
• Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities  
  Jain P, Kantarjian H, Nazha A, O'Brien S, Jabbour E, Romo CG, Pierce S, Cardenas-Turanzas M, Verstovsek S, Borthakur G, Ravandi F, Quintás-Cardama A, Cortes J, Blood, 6/1/2013
• Treatment of hairy cell leukemia during pregnancy: are purine analogues and rituximab viable therapeutic options  
  Daver N, Nazha A, Kantarjian HM, Haltom R, Ravandi F, Clin Lymphoma Myeloma Leuk, 2/1/2013
• Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities  
  Jain P, Kantarjian H, Nazha A, O'Brien S, Jabbour E, Romo CG, Pierce S, Cardenas-Turanzas M, Verstovsek S, Borthakur G, Ravandi F, Quintas-Cardama A, Cortes J, Blood, 1/1/2013
• Pharmacotherapy of polycythemia vera  
  Tam CS, Nazha A, Verstovsek S, Expert Opinion on Orphan Drugs, 1/1/2013
• Join now to see all

Abstracts/Posters

• Epigenomic Signatures in Myelodysplastic Syndrome Patients As Predictors of Donor Compatibility and Transplant Outcome
  Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Geno-Clinical Model for the Diagnosis of Bone Marrow Myeloid Neoplasms
  Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS)
  Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Timing for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Chronic Myelomonocytic Leukemia (CMML): A Joint Study from the International MDS/MPN Working Gr...
  Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Interactions between Donor Activating Killer Immunoglobulin-like Receptors (KIRs) and Somatic Mutations and Their Association with Outcomes after Allogeneic Hematopoie...
  Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Determinants of Fitness for Intensive Therapy Among Acute Myeloid Leukemia (AML) Patients
  Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Large Granular Lymphocytic Leukemia Coexists with Clonal Hematopoiesis of Indeterminate PotentialClinically Relevant Abstract
  Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Can Monosomy 7 be Targeted By Next Generation Cereblon-Modulating Agents?
  Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Pattern of Somatic Mutation Changes from Diagnosis to Relapse Following Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Acute Myeloid Leukemia (AML) and My...
  Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• ANKRD26 Coding Variants Presenting with Giant Platelets and a Predisposition to Myeloid Neoplasia
  Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• How Morphologic Features Are Shaped By Underlying Somatic Genotype in MDS
  Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Mutational Patterns and Clonal Architecture of Therapy-Related Acute Myeloid Leukemia
  Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Identifying Factors That Predict for Unplanned Readmissions for Acute Myeloid Leukemia Patients Receiving Consolidation Cytarabine Based Therapies
  Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• The Impact of Comorbidities and Organ Dysfunction Commonly Used for Clinical Trial Eligibility Criteria on Outcome in Acute Myeloid Leukemia (AML) Patients Receiving I...
  Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• First in Human Study of SEL24/MEN1703, First in Class, Orally Available Dual PIM/FLT3 Kinase Inhibitor, in Patients with Acute Myeloid Leukemia
  Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• FA Gene Carrier Status Predisposes to Myeloid Neoplasms and Bone Marrow Failure in AdultsClinically Relevant Abstract
  Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Mutational Type and Configuration of an Individual Gene May Differentially Impact the Clinical and Phenotypic Features
  Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• SEL120 _ a First-in-Class CDK8/19 Inhibitor As a Novel Option for the Treatment of Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome - Data from Preclinica...
  Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Are Racial Disparities in Acute Myeloid Leukemia (AML) Clinical Trial Enrollment Associated with Comorbidities and/or Organ Dysfunction?
  Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Eltrombopag Creates a Transient Chemical Phenocopy of TET2 Loss of Function That Contributes to Hematopoietic Precursor ExpansionClinically Relevant Abstract
  Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia (AML) Undergoing Remission Induction Therapy
  Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Molecular Dissection of Del(5q): Distinction between Primary and Secondary Del(5q) and Pathogenetic Implications
  Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Predicting Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes (MDS) Using Artificial Intelligence (AI)
  Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Towards Molecularly Informed Acute Myeloid Leukemia Subtyping Reflective of Pathogenesis
  Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Personalized Prediction Model to Risk Stratify Patients with Acute Myeloid Leukemia (AML) Using Artificial Intelligence
  Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• The Molecular Maelstrom of Myelodysplastic Syndromes (MDS) 
  60th American Society of Hematology Annual Meeting - 12/2/2018
• Genomic Biomarkers Predict Response/Resistance to Lenalidomide in Non-Del(5q) Myelodysplastic Syndromes 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Association of MHC Class I Chain-Related Gene a (MICA) Polymorphisms with Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Geno-Clinical Model to Aid in the Diagnosis of Myelodysplastic Syndrome (MDS) Versus Chronic Myelomonocytic Leukemia (CMML) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• TP53 Mutations in Myeloid Neoplasm Patients with and without Significant Personal and Family History of CancerClinically Relevant Abstract 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Stem Cell Transplant in Patients with Myelodysplastic Syndromes: On Behalf of the CIBMTR Ch... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Genotype-Resultant Morphology of Myelodysplastic Syndromes (MDS) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Survival Outcomes of Patients with Therapy-Related Acute Myeloid Leukemia in the United States 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Differences in Genomic Patterns between African Americans and Whites with Acute Myeloid Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Biallelic TET2 Inactivation in Myeloid Neoplasia: From Clonal Hierarchy to Clinical Phenotypes 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Clinical Outcomes for Patients with Myeloid Malignancies Harboring IDH1/2mutations after Intensive Chemotherapy 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• The Molecular Maelstrom of Myelodysplastic Syndromes (MDS) 
  60th American Society of Hematology Annual Meeting - 12/1/2018
• Somatic Mutational Model to Predict Response to Hypomethylating Agents (HMAs) in Myelodysplastic Syndromes (MDS). 
  Washington, DC - 1/1/2015
• Mutational Model to Predict Response to Hypomethylating Agents (HMAs) in Myelodysplastic Syndromes (MDS). 
  Houston, TX - 1/1/2015
• A Novel Prognostic Model in Heavily Treated Patients with Myelodysplastic Syndromes (MDS). 
  San Francisco, CA - 1/1/2014
• A Novel Prognostic Model for Risk Stratification in Younger Patients with Intermediate Risk Acute Myeloid Leukemia (AML). 
  Houston, TX - 1/1/2014
• Clofarabine, Idarubicin, and Cytarabine (CIA) as frontline therapy for patients younger than 61 years with newly diagnosed acute myeloid leukemia 
  San Diego, CA (2011); Atlanta, GA (2012) - 12/1/2012
• Clofarabine, Idarubicin, and Cytarabine (CIA) as frontline therapy for patients younger than 61 years with newly diagnosed acute myeloid leukemia. 
  Atlanta, GA - 1/1/2012
• Join now to see all